Finoriq research workspace
AMGEN INC (AMGN) Historical Metrics
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Review AMGN fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Company
- AMGEN INC (AMGN)
- Ticker
- AMGN
- Market Cap
- $197.1B
- Latest Price
- $365.2
- Industry
- Biotech & Pharma
AMGEN INC (AMGN) Current Valuation Metrics
Static valuation preview for AMGEN INC (AMGN). Market data retrieved 2026-06-17. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 23.5x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 4.93x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 17.1x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 4.3% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 5.9% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.